Virpax Pharmaceuticals (VRPX) Competitors $0.01 0.00 (0.00%) As of 08/8/2025 11:16 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. SYRS, CAPS, VINC, BON, UPC, NAVB, SMFL, SCPS, EVLO, and CMRAShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Syros Pharmaceuticals (SYRS), Capstone Therapeutics (CAPS), Vincerx Pharma (VINC), Bon Natural Life (BON), Universe Pharmaceuticals (UPC), Navidea Biopharmaceuticals (NAVB), Smart for Life (SMFL), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Its Competitors Syros Pharmaceuticals Capstone Therapeutics Vincerx Pharma Bon Natural Life Universe Pharmaceuticals Navidea Biopharmaceuticals Smart for Life Scopus BioPharma Evelo Biosciences Comera Life Sciences Virpax Pharmaceuticals (NASDAQ:VRPX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more risk & volatility, VRPX or SYRS? Virpax Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Which has better earnings & valuation, VRPX or SYRS? Virpax Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/ASyros Pharmaceuticals$386K0.08-$164.57M-$3.030.00 Do analysts prefer VRPX or SYRS? Syros Pharmaceuticals has a consensus target price of $3.33, suggesting a potential upside of 302,930.30%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Virpax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer VRPX or SYRS? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Syros Pharmaceuticals Neutral Is VRPX or SYRS more profitable? Virpax Pharmaceuticals' return on equity of -1,554.34% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Syros Pharmaceuticals N/A -3,369.56%-97.04% Do insiders and institutionals have more ownership in VRPX or SYRS? 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummarySyros Pharmaceuticals beats Virpax Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14K$857.25M$5.52B$9.72BDividend YieldN/A4.84%4.60%4.12%P/E RatioN/A1.1430.0124.75Price / SalesN/A26.66450.0597.82Price / CashN/A19.5636.7758.47Price / Book0.016.548.185.59Net Income-$15.19M-$4.07M$3.26B$265.99M7 Day PerformanceN/A121.77%6.13%5.06%1 Month PerformanceN/A1.87%0.07%0.61%1 Year PerformanceN/A22.82%36.31%22.82% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-100.0%$14KN/A0.007SYRSSyros Pharmaceuticals4.0332 of 5 stars$0.01-50.0%$3.33+33,233.3%-100.0%$268K$386K0.00120Gap UpCAPSCapstone TherapeuticsN/A$1.60+2.6%N/AN/A$256K$44.88M0.0038Positive NewsVINCVincerx Pharma2.6744 of 5 stars$0.05+0.9%$40.00+85,736.9%-99.6%$244KN/A0.0060News CoverageUpcoming EarningsGap DownBONBon Natural LifeN/A$1.37-2.5%N/A-97.3%$228K$23.84M0.00100Gap DownUPCUniverse PharmaceuticalsN/A$3.97-6.5%N/A-99.8%$170K$19.29M0.00220News CoverageNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010SMFLSmart for LifeN/A$0.00-90.5%N/A-99.8%$16K$11.11M0.00110Gap UpHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002 Related Companies and Tools Related Companies SYRS Alternatives CAPS Alternatives VINC Alternatives BON Alternatives UPC Alternatives NAVB Alternatives SMFL Alternatives SCPS Alternatives EVLO Alternatives CMRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
